When the UK started giving people the Pfizer-BioNTech vaccine, researchers at the University of Oxford and major pharmaceutical company AstraZeneca said the Oxford Covid-19 vaccine candidate has a better immune response when a regimen is used. two full doses instead of a full-dose regimen followed by a half booster dose.
Read also | European leaders isolate themselves after Macron tests positive COVID-19
The vaccine candidate, which has been licensed to AstraZeneca, has published interim study results in an advanced stage showing greater efficacy when a half dose is followed by a full dose, compared to a full two-dose regimen, although it is more work must be done to affirm the result.
Details of the Phase I / II clinical trials released Thursday did not refer to the half-dose / full-dose regimen, which Oxford said was “unplanned” but approved by regulators.
The university said it explored two dosing regimens in the early trial stages, a full-dose / full-dose regimen and a full-dose / half-dose regimen, studied as a possible ‘dose reduction’ strategy.
“The booster doses of the vaccine have both been shown to induce stronger antibody responses than a single dose, the standard dose / standard dose that induces the best response,” the university said in a statement.
The vaccine “stimulates extensive antibody and T cell functions,” he said after publishing additional data from Phase I / II clinical trials.
(With input from agencies)